6:08 PM
 | 
Feb 27, 2013
 |  BC Extra  |  Politics & Policy

SCOTUS backs class certification in Amgen case

The U.S. Supreme Court ruled 6-3 on Wednesday that shareholders may sue Amgen Inc. (NASDAQ:AMGN) as a class in a securities fraud case alleging the biotech misled investors about the safety of its anemia drugs Aranesp darbepoetin...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >